Reclast (Zoledronic Acid) FDA Approval History

Original Approval: Zometa for Oncology Indications (2001)

The FDA approved zoledronic acid 4 mg (branded Zometa) on August 20, 2001, under NDA 021223 for treatment of hypercalcemia of malignancy in patients who failed adequate hydration. This made zoledronic acid the most potent bisphosphonate available for IV administration, replacing pamidronate as the preferred agent in many oncology settings.

Novartis submitted the application based on two randomized, double-blind trials comparing zoledronic acid 4 mg and 8 mg to pamidronate 90 mg in 287 patients with hypercalcemia of malignancy. The 4 mg dose normalized serum calcium in 88.4% of patients by day 10 compared to 69.7% for pamidronate (FDA Drugs@FDA approval package). The 8 mg dose was later dropped from the label due to renal toxicity signals.

In February 2002, the FDA expanded the Zometa indication to include patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy, and for osteolytic lesions of multiple myeloma. This expansion rested on three large phase III trials showing reduced skeletal-related events compared to pamidronate (pubmed.ncbi.nlm.nih.gov/11844818).

The HORIZON Program and Reclast Approval (2007)

The regulatory path toward an osteoporosis indication required a fundamentally different formulation and dosing strategy. Novartis developed the 5 mg once-yearly IV infusion specifically for metabolic bone disease, filing it under a separate NDA (021817) with the brand name Reclast.

The HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly, Key Fracture Trial) enrolled 7,765 postmenopausal women aged 65 to 89 with femoral neck T-scores of -2.5 or worse. After three annual infusions, zoledronic acid reduced morphometric vertebral fractures by 70% (3.3% vs. 10.9%, relative risk 0.30 to 95% CI 0.24 to 0.38) and hip fractures by 41% (1.4% vs. 2.5%, hazard ratio 0.59 to 95% CI 0.42 to 0.83) compared to placebo (pubmed.ncbi.nlm.nih.gov/17476007). These results were published in the New England Journal of Medicine in May 2007 [1].

On August 17, 2007, the FDA approved Reclast 5 mg IV once yearly for the treatment of postmenopausal osteoporosis. The approval simultaneously included Paget disease of bone, based on a separate 6-month comparative trial against risedronate showing superior therapeutic response (96% vs. 74%, P<0.001) (pubmed.ncbi.nlm.nih.gov/15689584) [2].

Label Expansions: 2008 to 2012

The Reclast label underwent several significant expansions in the years following initial approval, each supported by dedicated registration trials or supplemental analyses.

Glucocorticoid-Induced Osteoporosis (April 2008). The FDA approved Reclast for prevention and treatment of glucocorticoid-induced osteoporosis in men and women expected to remain on glucocorticoids (prednisone ≥7.5 mg/day equivalent) for at least 12 months. The supporting trial randomized 833 patients to zoledronic acid 5 mg annually or risedronate 5 mg daily. Lumbar spine BMD increased 4.06% with zoledronic acid vs. 2.71% with risedronate at 12 months (P<0.001) (pubmed.ncbi.nlm.nih.gov/19064530) [3].

Male Osteoporosis (December 2008). This supplemental approval recognized that the glucocorticoid trial included men and that the HORIZON-RFT (Recurrent Fracture Trial) provided additional male-specific data. HORIZON-RFT enrolled 2,127 patients (24% male) with recent hip fracture and showed a 35% reduction in all clinical fractures and a 28% reduction in all-cause mortality (P=0.01) (pubmed.ncbi.nlm.nih.gov/17876019) [4].

Osteoporosis Prevention (September 2009). The FDA approved Reclast 5 mg IV once every two years for prevention of postmenopausal osteoporosis. The supporting trial randomized 581 osteopenic postmenopausal women to a single infusion of zoledronic acid or placebo, showing significant BMD gains at the lumbar spine (4.0% vs. 1.2%) and total hip (2.2% vs. 0.4%) at 24 months (pubmed.ncbi.nlm.nih.gov/19671655) [5].

Post-Market Safety Communications

The FDA has issued multiple safety communications and label revisions for zoledronic acid since approval, reflecting the drug's broad use and long skeletal half-life.

Renal Impairment (September 2011). The FDA issued a Drug Safety Communication requiring healthcare professionals to screen serum creatinine before each Reclast infusion. The infusion time was already labeled at no less than 15 minutes, but cases of acute renal failure requiring dialysis and, rarely, death, had been reported in patients receiving the infusion in under 15 minutes or in those with pre-existing renal impairment. Reclast is contraindicated when creatinine clearance is <35 mL/min (fda.gov safety communication) [6].

Atypical Femoral Fractures (October 2010, updated 2013). The FDA required a class-wide label update for all bisphosphonates, including zoledronic acid, to warn of atypical subtrochanteric and diaphyseal femoral fractures. A task force report from the American Society for Bone and Mineral Research estimated incidence at 3.2 to 50 per 100,000 person-years with bisphosphonate use beyond 3 years, compared to 0.3 per 100 to 000 in non-users (pubmed.ncbi.nlm.nih.gov/24120886) [7].

Osteonecrosis of the Jaw (2005 advisory, label updates through 2022). ONJ risk was first flagged via an FDA advisory in 2005 for IV bisphosphonates in oncology. For the osteoporosis dose (5 mg yearly), the HORIZON trials reported ONJ in 1 of 7,765 zoledronic acid-treated patients vs. 1 of 7,762 placebo patients. A large Kaiser Permanente cohort study estimated ONJ incidence at 0.8 to 1.2 per 100,000 patient-years of osteoporosis-dose exposure (pubmed.ncbi.nlm.nih.gov/27907950) [8].

Musculoskeletal Pain (January 2008). The FDA issued an early safety alert noting severe and sometimes incapacitating bone, joint, or muscle pain in bisphosphonate users, which may occur days to months after initiation. The alert applied to all oral and IV bisphosphonates.

Generic Approval and Market Competition

The first generic zoledronic acid 5 mg/100 mL IV solution received FDA approval in October 2013, manufactured by Apotex. Multiple additional generics have since entered the market, including products from Mylan, Hospira (now Pfizer), Sun Pharma, and Fresenius Kabi.

Generic entry reduced out-of-pocket costs meaningfully. Average wholesale price for the branded Reclast infusion was approximately $1,200 to $1,400 before generics; generic zoledronic acid now ranges from $200 to $500 for the drug product alone, though total cost of administration (including IV infusion in an office or infusion center) typically adds $150 to $400 depending on insurance and setting (accessdata.fda.gov approved generics) [9].

The FDA's Sentinel System post-market analysis, published in collaboration with the Mini-Sentinel pilot, evaluated over 43,000 new users of IV zoledronic acid between 2007 and 2012. The analysis confirmed the acute-phase reaction rate (fever, myalgia, arthralgia within 3 days) at 31.4% after the first infusion but declining to 6.6% after the second, consistent with the original HORIZON-PFT findings (pubmed.ncbi.nlm.nih.gov/25234862) [10].

International Regulatory Context

Outside the United States, zoledronic acid has been approved by the European Medicines Agency (EMA) under the brand names Aclasta (osteoporosis) and Zometa (oncology). The EMA granted marketing authorization for Aclasta in April 2005, two years before the FDA approved Reclast. This earlier European approval was based on the same HORIZON program data submitted under accelerated timelines.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has issued safety referrals consistent with FDA actions, including atypical femoral fracture warnings (2011) and ONJ class labeling (2015). A notable divergence: the EMA recommends consideration of a "drug holiday" after 3 years of IV bisphosphonate therapy in lower-risk patients, while the FDA label does not specify optimal treatment duration but references the Endocrine Society guideline recommending reassessment after 3 annual infusions (endocrine.org clinical practice guideline) [11].

Current Label Status and Clinical Positioning

As of 2026, the Reclast (zoledronic acid) 5 mg label carries six approved indications:

1. Treatment of osteoporosis in postmenopausal women
2. Prevention of osteoporosis in postmenopausal women
3. Treatment to increase bone mass in men with osteoporosis
4. Treatment and prevention of glucocorticoid-induced osteoporosis
5. Treatment of Paget disease of bone
6. (Under Zometa 4 mg) Hypercalcemia of malignancy and bone metastases

The American Association of Clinical Endocrinology (AACE) 2020 guidelines position IV zoledronic acid as a first-line option for patients at high fracture risk who cannot tolerate oral bisphosphonates, and as a preferred agent when adherence concerns make weekly or monthly oral dosing impractical. The guidelines specifically note that a once-yearly infusion eliminates the upper-GI absorption requirements and fasting protocols that reduce oral bisphosphonate compliance (aace.com osteoporosis guidelines) [12].

Dr. Dennis Black, principal investigator of HORIZON-PFT and professor of epidemiology at UCSF, noted in the original trial publication: "A single annual infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures" [1]. The Endocrine Society's 2022 guideline update states: "Intravenous zoledronic acid is recommended as initial therapy in patients at high risk of fracture, particularly when oral bisphosphonates are contraindicated or when adherence is a concern" [11].

The drug's 25-year regulatory history reflects a successful lifecycle management strategy: a single molecule serving both oncology (high-dose, frequent infusion) and metabolic bone disease (lower-dose, annual infusion) under separate NDAs, with post-market surveillance confirming a favorable benefit-risk ratio at the osteoporosis dose for the vast majority of patients with creatinine clearance ≥35 mL/min.